Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CancerHetero

Financiado

Cerrado

Dissection of tumor heterogeneity in vivo

It is now widely accepted that tumors are composed of heterogeneous population of cells, which contribute to many aspects of treatment resistance observed in clinic. Despite the acknowledgment of the tumor cell heterogeneity, litt... ver más

31/05/2020

GERMAN CANCER RESE...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-31

ERC-CoG-2014: ERC Consolidator Grant

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

GERMAN CANCER RESEARCH CENTE...

2.00M€ | Lider

CEMENTOS CAPA,

452.94K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TrackingTumorStates Tracking and Targeting Tumor States at single cell resolutio... 3M€ Cerrado

SAF2014-55944-R IDENTIFICACION DE LOS MECANISMOS MOLECULARES QUE REGULAN LA... 145K€ Cerrado

INTRAHETEROSEQ Molecular characterization of the role of intra tumor hetero... 1M€ Cerrado

CLONCELLBREAST CLONAL AND CELLULAR HETEROGENEITY OF BREAST CANCER AND ITS D... 2M€ Cerrado

SAF2014-57791-REDC BIOLOGIA DEL CANCER 45K€ Cerrado

GBM_Cellular_States Deciphering and targeting cellular states in glioblastoma 2M€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2015-05-04
Fecha Fin: 2020-05-31

Líder del proyecto

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto It is now widely accepted that tumors are composed of heterogeneous population of cells, which contribute to many aspects of treatment resistance observed in clinic. Despite the acknowledgment of the tumor cell heterogeneity, little evidence was shown about complexity and dynamics of this heterogeneity in vivo, mainly because of lacking flexible genetic tools which allow sophisticated analysis in primary tumors. We recently developed a very efficient mouse somatic brain tumor model which have a full penetrance of high grade glioma development. Combination of this model with several transgenic mouse lines allow us to isolate and track different population of cells in primary tumors, most importantly, we also confirmed that this can be done on single cell level. Here I propose to use this set of valuable genetic tools to dissect the cellular heterogeneity in mouse gliomas. First we will perform several single cell lineage tracing experiment to demonstrate the contribution of brain tumor stem cell, tumor progenitors as well as the relatively differentiated cells, which will provide a complete data sets of clonal dynamics of different tumor cell types. Second we will further perform this tracing experiment with the presence of conventional chemotherapy. Third we will perform single cell RNA sequencing experiment to capture the molecular signature, which determines the cellular heterogeneity, discovered by single cell tracing. This result will be further validated by analysis of this molecular signatures in human primary tumors. We will also use our established in vivo target validation approach to manipulate the candidate molecular regulators to establish the functional correlation between molecular signature and phenotypic heterogeneity. This project will greatly improve our understanding of tumor heterogeneity, and possibly provide novel approaches and strategies of targeting human glioblastomas.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores